Source: http://otp-journal.com.ua/article/view/18039
Timestamp: 2019-04-25 17:57:40+00:00

Document:
The article contains results of multinational multicentre trials RECORD for studying the clinical application of Xarelto® (Rivaroxaban) for prevention of thrombosis. The author shows that a long-term taking of Xarelto® considerably decreases the rate of development of venous thromboembolism, including symptomatic thromboses, in patients after total hip joint arthroplasty versus short-term prophylaxis with Enoxaparin plus placebo.
Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial [Text] / V. V. Kakkar, T. P. Corrigan, D. P. Fossard et al. // Lancet. — 1975. — V. 306. — P. 45–51.
NIH. Prevention of venous thrombosis and pulmonary embolism [Text] // NIH consensus statement. — 1986. — V. 6. — P. 1–8.
Making health care safer: a critical analysis of patient safety practices [Електронний ресурс] / K. G. Shojania, B. W. Duncan, K. M. McDonald, R. M. Wachter. — Режим доступу: http://www.ahrq.gov/clinic/ptsafety/pdf/ptsafety.pdf (accessed May 23, 2008).
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [Text] / W. H. Geerts, G. F. Pineo, J. A. Heit et al. // Chest. — 2004. — V. 126. — P. 338–400.
Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism [Text] / A national clinical guideline. — Edinburgh: SIGN Publication, 2002.
NICE. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery [Електронний ресурс]: NICE clinical guidelines. — Режим доступу: www.nice.org.uk/nicemedia/pdf/VTEFullGuide.pdf (accessed May 23, 2008).
Eikelboom J. W. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials [Text]/ J. W. Eikelboom, D. J. Quinlan, J. D. Douketis // Lancet. — 2001. — V. 358. — P. 9–15.
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review [Text] / R. D. Hull, G. F. Pineo, P. D. Stein et al. // Ann Inter.
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry [Text] / D. Warwick, R. J. Friedman, G. Agnelli et al. // J Bone Joint Surg Br. — 2007. — V. 89. — P. 799–807.
Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial [Text] // Lancet. — 2000. — V. 355. — P. 1295–302.
American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty [Електронний ресурс]. — Режим доступу: www.aaos.org/Research/guidelines/PE_guideline.pdf (accessed May 23, 2008).
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry [Text] / F. A. Anderson Jr., J. Hirsh, K. White, R. H. Fitzgerald Jr. // Chest. — 2003. — V. 124. — P. 349–356.
Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians — are they appropriate for orthopaedic surgery? [Text] / J. J. Callaghan, L. D. Dorr, G. A. Engh et al. // J. Arthroplasty. — 2005. — V. 20. — P. 273–274.
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty [Text] / R. H. White, P. S. Romano, H. Zhou, J. Rodrigo, W. Bargar // Arch Intern Med. — 1998. — V. 158. — P. 1525–31.
Friedman R. J. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty [Text] / R. J. Friedman // J Am Acad Orthop Surg. — 2007. — V. 15. — P. 148–155.
A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [Text] / B. I. Eriksson, L. C. Borris, O. E. Dahl et al. // Circulation. — 2006. — V. 114. — P. 2374–2381.
Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement [Text] / B. I. Eriksson, L. Borris, O. E. Dahl et al. // J. Thromb Haemost. — 2006. — V. 4. — P. 121–128.
Dose-escalation study of rivaroxaban (BAY 59-7939) — an oral, direct factor Xa inhibitor — for the prevention of venous thromboembolism in patients undergoing total hip replacement [Text] / B. I. Eriksson, L. C. Borris, O. E. Dahl et al. // Thromb Res. — 2007. — V. 120. — P. 685–693.
Rabinov K. Roentgen diagnosis of venous thrombosis in the leg [Text] / K. Rabinov, S. Paulin // Arch Surg. — 1972. — V. 104. — P. 134–144.
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [Text] / D. Bergqvist, G. Benoni, O. Bjorgell et al. // N Engl J Med. — 1996. — V. 335. — P. 696–700.
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty — the Danish Prolonged Prophylaxis (DaPP) Study [Text] / M. R. Lassen, L. C. Borris, B. S. Anderson et al. // Thromb Res. — 1998. — V. 89. — P. 281–287.
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group [Text] / P. C. Comp, T. E. Spiro, R.J. Friedman et al. // J. Bone Joint Surg Am. — 2001. — V. 83-A. — P. 336–345.
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study [Text] / P. Prandoni, O. Bruchi, P. Sabbion et al. // Arch Intern Med. — 2002. — V. 162. — P. 1966–1971.
Prolonged thromboprophylaxis following hip replacement surgery — results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) [Text] / O. E. Dahl, G. Andreassen, T. Aspelin et al. // Thromb Haemost. — 1997. — V. 77. — P. 26–31.
Low-molecular-weight heparin prophylaxis using extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind randomized comparison. North American Fragmin Trial Investigators [Text] / R. D. Hull, G. F. Pineo, C. Francis et al. // Arch Intern Med. — 2000. — V. 160. — P. 2208–2215.
Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo [Text] / A. Planes, N. Vochelle, J. Y. Darmon et al. // Lancet. — 1996. — V. 348. — P. 224–228.
Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial [Text] / B. I. Eriksson, L. C. Borris, R. J. Friedman et al. // Blood. — 2007. — V. 110: abstract 6.
Rivaroxaban — an oral, direct factor Xa inhibitor — for thromboprophylaxis after total knee arthroplasty: the RECORD3 trial [Text] / M. R. Lassen, A.G. G. Turpie, N. Rosencher et al. // Blood. — 2007. — V. 110: abstract 308.
Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe [Text] / N. Rosencher, H. E. Kerkkamp, G. Macheras et al. // Transfusion. — 2003. — V. 43. — P. 459–469.
Dahl O. E. Orthopaedic surgery as a model for drug development in thrombosis [Text] / O. E. Dahl // Drugs. — 2004. — V. 64 (suppl 1). — P. 17–25.
Kakkar A. K. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines [Text] / A. K. Kakkar, B. L. Davidson, S. K. Haas // J. Thromb Haemost. — 2004. — V. 2. — P. 221–227.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.